Tramadol controlled release - e-Therapeutics
Alternative Names: ETS-6103; ETX6103; Tramadol extended release - e-Therapeutics; Tramadol hydrochloride; Tramadol sustained release - e-Therapeutics; ViotraLatest Information Update: 05 Nov 2023
At a glance
- Originator e-Therapeutics
- Class Anisoles; Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Major depressive disorder
Most Recent Events
- 22 Mar 2016 e-Therapeutics completes a phase IIb trial for Major depressive disorder in the United Kingdom (NCT02014363) prior to March 2016
- 07 Jan 2016 Tramadol controlled release - e-Therapeutics is available for licensing as of 07 Jan 2016. http://www.etherapeutics.co.uk/
- 01 Jun 2015 e-Therapeutics completes enrolment in its phase IIb trial for Major depressive disorder in United Kingdom